Paige Archives - AiThority

Paige Unveils Game-Changing AI That Revolutionizes Cancer Detection Across Multiple Tissue Types

Business Wire — Tue, 09 Jan 2024 09:12:28 +0000

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications announced the release of a groundbreaking product developed from Paige’s Pathology Foundation Model, Virchow. Built using one of the largest libraries of digitized images, utilizing unique computational resources provided by Microsoft Research, Paige has developed the first application that can detect cancer across more than 17 different tissue types including skin, lung, and the gastrointestinal tract, along with multiple rare tumor types and metastatic deposits.

“Beyond its multi-tissue capabilities, the Foundation Model and the use of its embeddings can also be leveraged as a critical building block in a variety of upstream and downstream applications across the entire healthcare continuum”

Traditionally, development of pathology cancer detection AI applications required large datasets, one tissue type at a time, often taking months or years to build at clinical grade. By leveraging its unique Foundation Model, Paige has surpassed these limitations. With data derived from over 4 million digitized slides, Paige’s innovative approach removes the constraints of developing single tissue products, making it possible to efficiently create cancer detection AI applications across a multitude of tumor types, a first in AI-based cancer diagnosis.

“The early success of our Foundation Model has been possible due to the size, quality, and diversity of the datasets we used to build it,” said Siqi Liu, PhD, director of AI Science at Paige. “Paige has access to one of the largest and most highly regarded pathology datasets globally, which allows us to leverage cutting-edge deep-learning approaches to train systems to detect common, complex, and even very rare cancer entities. Paige’s development provides the pathology community with the most powerful tools for diagnosis, prognosis, biomarker development, and targeted selection of patients for precision therapy,” he continued.

The exceptional performance of Paige’s multi-cancer application across various tissue types is considered state-of-the art in cancer pathology AI. Paige is committed to ensuring its AI applications are clinical grade and will therefore continue to seek FDA regulatory oversight for products based on the Foundation Model technology.

“We see FDA clearance as being critical to ensure that regulatory and safety standards are being upheld in the application of AI in cancer diagnostics across tumor types,” said Andy Moye, CEO of Paige. “Paige remains at the forefront of innovation and regulatory milestones, and we expect this multi-tissue detection model to benefit patients, pathologists, and the broader medical community. Our commitment to excellence is exemplified by this groundbreaking achievement, marking a significant leap forward in cancer diagnostics.”

“Beyond its multi-tissue capabilities, the Foundation Model and the use of its embeddings can also be leveraged as a critical building block in a variety of upstream and downstream applications across the entire healthcare continuum,” said Razik Yousfi, Senior Vice President of Technology at Paige. “By combining the outputs of the Foundation Model with data types from other modalities, including genomics, radiology, and other health data, one can derive exponentially greater insights about the nature of cancer, its behavior, and response to specific treatments.”

Recommended AI News: OPENLANE Launches Visual Boost AI to Pinpoint Vehicle Damage

[To share your insights with us, please write to sghosh@martechseries.com]

The post Paige Unveils Game-Changing AI That Revolutionizes Cancer Detection Across Multiple Tissue Types appeared first on AiThority.

Paige and Nuance Collaborate to Establish the Largest Consultation Network in Pathology

Business Wire — Tue, 28 Nov 2023 14:14:58 +0000

Paige will leverage the Nuance PowerShare image sharing network for expert second opinions in pathology

At the Radiological Society of North America’s (RSNA) 109th Scientific Assembly and Annual Meeting, Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, announced it has teamed up with Nuance, a Microsoft company, to create the largest digital consultation network in pathology. This secure best-in-class platform will revolutionize collaboration among U.S. pathologists, making consultations faster and more efficient. The platform leverages the scale and capabilities of Nuance’s PowerShare image sharing network together with Paige’s track record and expertise in digital pathology and its leading FDA approved viewer.

By merging Paige’s cutting-edge digital pathology tools, like FullFocus^® and FullFolio™, with PowerShare, Nuance’s nationwide image sharing network, connecting over 14,000 sites for seamless medical image sharing, laboratories with any type of digital capability gain frictionless access to top-tier hospitals and healthcare systems for expert consultations, enhancing the diagnostic process.

This collaboration addresses common challenges in external consultations, like time constraints, glass slide damage risks, and high costs. It connects pathologists with peers and world-class experts, stimulates growth in reference centers’ consultation services, and streamlines healthcare operations, ultimately reducing time to diagnosis and costs whenever pathology cases are shared between institutions.

“Our collaboration with Nuance heralds a new dawn in pathology where pathology consultation becomes easier and cheaper and where patients can get access to the right experts at the right time. Together, Paige and Nuance seek to break down traditional barriers to cancer diagnosis and accelerate the wider adoption of digital pathology,” said Andy Moye, CEO of Paige.

“By leveraging the Nuance PowerShare image sharing network as the nationwide platform for its digital pathology consultation solution, Paige is exemplifying the innovation and forward-looking leadership that’s needed to advance collaborative care and meaningfully improve healthcare costs and outcomes,” said Peter Durlach, Corporate Vice President and Chief Strategy Officer, Health and Life Sciences, Microsoft. “This digital pathology solution is an excellent and important addition to the growing portfolio of collaborative radiology, medical devices and other solutions that harness the PowerShare network’s ubiquity, reliability and security to support the earlier detection and treatment of disease and empower physicians to deliver high-quality care.”

“In the end, it’s the patients who stand to benefit the most,” concluded Moye. “The accessibility and swiftness of the digital consultation system mean that every patient, irrespective of their location, can benefit from expert opinions, ensuring optimal quality care and faster diagnoses.”

[To share your insights with us, please write to sghosh@martechseries.com]

The post Paige and Nuance Collaborate to Establish the Largest Consultation Network in Pathology appeared first on AiThority.

Paige and Ohio State Wexner Medical Center Collaborate to Study How AI Tools Can Bring Accuracy and Efficiency to Prostate Cancer Diagnosis

Business Wire — Fri, 18 Aug 2023 09:53:24 +0000

The Multi-Arm Study Will Utilize Paige Prostate Detect, the Only FDA Approved AI in Pathology for Detecting Prostate Cancer

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, announced a collaboration with Ohio State University Wexner Medical Center (OSWMC) and its affiliated community hospitals. They will conduct a multi-arm clinical utility and health economics study to measure the accuracy, efficiency and cost-savings impact of using AI tools in diagnosing cancer in a community hospital setting. OSWMC will utilize the Paige Prostate Suite, including Paige Prostate Detect, the only FDA approved AI-powered pathology algorithm, to assess the differences between diagnoses made with and without the use of AI.

AiThority Interview Insights: AiThority Interview with Bret Greenstein, Partner, Data & AI at PwC

“The community setting has arguably the most to benefit from the Paige Prostate Suite, which is a virtual digital companion expert”

Paige Prostate has already been shown to improve the detection of prostate cancer. In this research, leading community hospital pathologists will be conducting a retrospective real-world data study to analyze differences in the accuracy and read efficiency with which general surgical pathologists detect, grade, and quantify prostate cancers with and without the assistance of the Paige Prostate Suite, compared to a subspecialist reference diagnosis. The study will also examine differences in time and resource utilization based on the use of AI. Qualitatively, this will help determine the impact of the Paige Prostate AI applications on community pathologists, factoring in subspecialist skill access, patient treatment and management pathways, and the level of confidence in diagnosis with and without Paige’s AI applications.

“The American Cancer Society estimates there will be more than 288,000 new cases of prostate cancer in the United States in 2023 alone, and more than 10 percent of them will be fatal,” said Dr. David Klimstra, Co-Founder and Chief Medical Officer at Paige. “The study by OSWMC and its affiliates, using Paige, will provide greater insight into the impact AI has on their diagnostic capabilities, and ultimately help pathologists and oncologists feel confident in the accuracy and efficiency of AI to support them in detecting, diagnosing and treating prostate cancer patients.”

Read More about AiThority Interview: AiThority Interview with Rebecca Jones, General Manager at Mosaicx

“The community setting has arguably the most to benefit from the Paige Prostate Suite, which is a virtual digital companion expert,” added Andrea Parke, Global Director of Clinical Science and Partnerships at Paige. “This novel study will not only investigate the impact of Paige Prostate on diagnostic accuracy in the community setting, but also measure the time and resource efficiencies that can be gained with an AI assisted workflow.”

OSWMC have curated the study cohort and aim to initiate study reads later this month.

“AI powered diagnostic solutions such as Paige are on their way to revolutionizing pathology practice,” said Dr. Swati Satturwar, Clinical Assistant Professor of Pathology and the study’s Principal Investigator. “This retrospective study in collaboration with Paige will showcase the effectiveness of AI in the community setting and will provide real-life evidence to enhance adoption of AI for routine clinical use.”

Paige uses the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a global scale. Paige is the first company to receive FDA approval for a clinical AI application in digital pathology. The same Paige technology empowers pharmaceutical companies to more effectively evaluate treatment options for patients and design new biomarkers for drug development so that every patient gets precise treatment options.

Latest AiThority Interview Insights : AiThority Interview with Dan O’Connell, Chief AI & Strategy Officer at Dialpad

[To share your insights with us, please write to sghosh@martechseries.com]

The post Paige and Ohio State Wexner Medical Center Collaborate to Study How AI Tools Can Bring Accuracy and Efficiency to Prostate Cancer Diagnosis appeared first on AiThority.

University of Florida College of Medicine Jacksonville Adopts Paige’s AI for Enhanced Cancer Diagnosis

Business Wire — Wed, 12 Jul 2023 08:58:17 +0000

Paige, a global leader in end-to-end digital pathology solutions and clinical artificial intelligence (AI) applications for diagnosing cancer, and University of Florida College of Medicine – Jacksonville announced the Department of Pathology and Laboratory Medicine’s decision to adopt Paige’s full portfolio of AI offerings for their lab, including the Paige Prostate Suite and Paige Breast Suite. Powered by the Paige Platform, which offers advanced whole-slide image viewing, seamless integration of Paige and third-party AI, and deep collaboration with industry-leading scanner and LIS vendors, these AI applications support pathologists in the difficult decisions they make every day, offering them greater clinical confidence and supporting them in delivering precision cancer diagnosis.

AiThority Interview Insights: How to Get Started with Prompt Engineering in Generative AI Projects

“We are excited to see the groundbreaking work they will accomplish with the assistance of the Paige Platform and are honored to provide the tools for their digital transformation.”

Paige’s clinic–ready AI applications will be introduced to pathologists for use as a diagnostic adjunct, helping them to manage growing demand for their services by offering greater diagnostic efficiency and accuracy across prostate and breast cancer cases. Rigorously tested and designed to work in a clinical setting, Paige’s AI empowers pathologists through every step in the diagnostic process and offers an added layer of confidence even in the most challenging cases.

Read More about AiThority Interview: AiThority Interview with Brigette McInnis-Day, Chief People Officer at UiPath

“The choice to adopt AI was made, first and foremost, with our patients in mind,” said Dr. Shahla Masood, Professor and Chair, Department of Pathology and Laboratory Medicine, University of Florida College of Medicine – Jacksonville. “We are committed to providing our patients with the best possible outcomes, and to improving the diagnostic experience for our pathologists. Using an AI-powered application saves our pathologists from the tedious and repetitive tasks involved in diagnosis, improves their diagnostic confidence and gives them the ability to focus their attention on the cases that need their expertise the most.”

The Paige Platform is the most robust and easily integrated solution on the market, making Paige the right partner to take the lab digital and continue to support them as the needs of their patients evolve over time.

“The University of Florida College of Medicine at Jacksonville is not only a prime example of excellent patient care, but a lab that is eager to push the entire field of pathology forward as pioneers in digital pathology,” said Dr. David Klimstra, Chief Medical Director of Paige. “We are excited to see the groundbreaking work they will accomplish with the assistance of the Paige Platform and are honored to provide the tools for their digital transformation.”

Latest AiThority Interview Insights : AiThority Interview with Abhay Parasnis, Founder and CEO at Typeface

[To share your insights with us, please write to sghosh@martechseries.com]

The post University of Florida College of Medicine Jacksonville Adopts Paige’s AI for Enhanced Cancer Diagnosis appeared first on AiThority.

Paige Applies the Power of AI to Improve Breast Cancer Diagnoses with the Launch of its Expanded Breast Suite

Business Wire — Thu, 15 Jun 2023 14:59:40 +0000

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer launched the enhanced Paige Breast Suite, a complete set of products designed to empower pathologists in their diagnosis of breast cancer, reduce the subjectivity and tedium of manual diagnosis, and increase diagnostic efficiency and confidence. The Paige Breast Suite includes Paige Breast Detect, Paige Breast Neoplasm, Paige Breast Mitosis, Paige Breast Lymph Node and HER2Complete, a comprehensive group of AI tools that help to support every step of breast cancer diagnosis and to streamline pathologists’ day-to-day workflows.

Latest Insights: Leverage Artificial Intelligence Tools to Reduce Fraud and Friction for Customers

“At the heart of every Paige offering is the highest level of patient care”

The Suite offers a state-of-the-art AI-powered tool for mitotic counting, which is a critical element of breast cancer diagnosis that is currently time consuming and subjective. In addition, Paige Breast Detect and Neoplasm enable pathologists to better prioritize their review of slides or entire cases by providing AI results throughout the diagnostic workflow to enhance efficiency. The Suite is built using the most advanced training techniques to be able to adapt to any lab without on-site tuning or calibration.

“At the heart of every Paige offering is the highest level of patient care,” said David Klimstra, M.D., Founder and Chief Medical Officer at Paige. “With the addition of Neoplasm and Mitosis detection to our Breast Suite, we assist pathologists in gaining greater efficiency and confidence in everyday tasks like mitotic counting. There are too few pathologists for the increasing demands of breast cancer diagnosis. Paige tackles the pathologist shortage by supporting breast cancer diagnosis and simultaneously providing greater confidence, reducing false negatives and increasing pathologists’ efficiency.”

Read: ChatGPT Is Much More Than A Data Prep Assistant

The Paige Breast Suite is clinical-grade and built to the highest regulatory standards. Leveraging the same core technology that earned Paige FDA-approval for Paige Prostate Detect*, which was built on thousands of slides from hundreds of global institutions, the Paige Breast Suite delivers high performance across diverse datasets and is fit for use in real-world clinical settings.

AiThority: The 3 Building Blocks to Make AI Accessible

[To share your insights with us, please write to sghosh@martechseries.com]

The post Paige Applies the Power of AI to Improve Breast Cancer Diagnoses with the Launch of its Expanded Breast Suite appeared first on AiThority.

Paige Introduces New AI-Based Biomarker Screening Advancement to Drastically Reduce Diagnostic Turnaround Times and Inform Precision Treatment Decisions

PRNewswire — Thu, 01 Jun 2023 18:33:43 +0000

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer,announced a new AI-based digital assay to support pathologists in the detection and diagnosis of microsatellite instability (MSI) status in colon cancers. Paige Colon MSI operates on whole slide images of hematoxylin and eosin (H&E)-stained slides alone, offering slide-level classification of MSI status in colon cancer samples* based on morphologies associated with the presence or absence of MSI/MMR phenotype. Paige Colon MSI is a new addition to Paige’s Colon Suite which also includes case and slide-level detection of suspicious regions including invasive carcinoma and high-grade dysplasia.

“Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review”

Paige Colon MSI aims to assist pathologists by providing additional insight in identifying those patients who may benefit from definitive MSI/MMR testing for one of the most common hereditary cancer syndromes and IO therapy. The system has been designed to be optimized for negative predictive value (NPV=0.99 when assessed on over 500 samples from various sources). AI results can be obtained immediately from digitized stained sections so there is no need to wait days to weeks for results for the ~85% of patients whose tumors are MS stable and could potentially avoid the expensive screening that is required today.¹

“Paige Colon MSI is another example of how the company is innovating to empower pathologists, transform pathology and improve the lives of patients with cancer,” said Dr. Joe Oakley, MD, Medical Director of Biomarker Development at Paige. “We used the most advanced machine learning methods available on the most robust dataset in the industry to improve AI detection of MSI in colon cancer. We hope to demonstrate that this assay will offer laboratories and healthcare systems a chance to reduce MSI screening costs and accelerate their workflows. We believe this represents an important first step to more comprehensive MSI and mismatch repair deficiency detection in cancers.”

Despite guideline recommendations, recent studies have shown not all patients are being tested for MSI status.Introducing Paige Colon MSI as a cost-effective and time-efficient assistive testing method may improve access to diagnostic testing for more patients by highlighting cases likely to harbor MSI, which should then be confirmed by immunohistochemistry or molecular methods to inform precision treatment decisions.

While colon cancer is the initial focus, Paige is working to develop subsequent enhancements to enable screening in additional cancer types.

Top AI ML Insights: AiThority Interview with Alex Mans, Founder and CEO at FLYR Lab

[To share your insights with us, please write to sghosh@martechseries.com]

The post Paige Introduces New AI-Based Biomarker Screening Advancement to Drastically Reduce Diagnostic Turnaround Times and Inform Precision Treatment Decisions appeared first on AiThority.

Paige Introduces Advanced Integration Capabilities to the Paige Platform, A Single Solution that Integrates the Entire Digital Pathology Ecosystem and Streamlines Workflows

Business Wire — Mon, 22 May 2023 09:58:32 +0000

Clinically Utilized by Labs Throughout the World, the Paige Platform is the Only Digital Pathology Solution Built for AI Offering Flexibility, Scalability, and Customization

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, introduced new advanced integration capabilities to the Paige Platform, a holistic web-based solution that enables complete digital pathology workflows and supports the evolving needs of today’s modern lab.

AiThority Interview Insights: AiThority Interview with Ramsey Masri, Chief Executive Officer at Ceres Imaging

“Paige is the only AI-powered digital pathology platform being used daily all over the world that offers truly open, secure and scalable API capabilities. The Paige Platform drives diagnostic confidence and efficiency for pathologists in their quest to diagnose cancer quickly and accurately every single time”

With Paige’s flexible platform at the nexus of the digital pathology ecosystem, labs and pathologists can connect their existing and future digital pathology applications into a single environment managed by Paige. The Platform’s flexibility is powered by a set of APIs that allow for unlimited vendor-neutral integrations and enable custom workflows to be built on top of Paige’s already robust native capabilities. In addition to integrating within the workflow, the solution enables seamless access to both Paige’s AI solutions and third-party AI applications. This helps to support labs in taking an iterative approach to digital pathology adoption, reducing upfront investment, avoiding vendor lock-in and making the digital transition a frictionless experience for the entire pathology department.

“Paige is the only AI-powered digital pathology platform being used daily all over the world that offers truly open, secure and scalable API capabilities. The Paige Platform drives diagnostic confidence and efficiency for pathologists in their quest to diagnose cancer quickly and accurately every single time,” said Andy Moye, Ph.D., Chief Executive Officer at Paige. “The open platform is thoughtfully designed to empower labs and pathologists to customize their workflows to their unique needs and leverage AI at all steps from case creation to reporting.”

Read More about AiThority Interview: AiThority Interview with Jim Kaskade, Chief Executive Officer at Conversica

The Paige Platform was developed for superior user experience and functionality, placing everything a digital pathologist may need at their fingertips, including diverse WSI scanner and LIS integration capabilities, a CE-IVD & UKCA marked and FDA-cleared whole slide image viewer^*, a digital case manager to help prioritize and streamline case review and immediate access to Paige and third-party AI applications. The Paige system is supported by sophisticated, economical data management and cloud-storage options.

The Paige Platform was developed against the most secure standards in the industry, achieving ISO 27001 certification. Paige is also HIPAA and GDPR compliant.

*In the United States, European Union & United Kingdom, FullFocus® (K201005) is cleared for clinical use with various scanner brands and models, including Philips Ultrafast, Leica AT2, Hamamatsu S60 and S360, and 3DHistech P1000 scanners.

Latest AiThority Interview Insights : AiThority Interview with Itamar Kandel, Chief Executive Officer at Vista.ai

[To share your insights with us, please write to sghosh@martechseries.com]

The post Paige Introduces Advanced Integration Capabilities to the Paige Platform, A Single Solution that Integrates the Entire Digital Pathology Ecosystem and Streamlines Workflows appeared first on AiThority.

Paige and Visiopharm Work Together to Deliver Advanced AI Cancer Diagnostic Support Through the Paige Platform

Business Wire — Fri, 05 May 2023 10:46:58 +0000

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications to assist in diagnosing cancer announced it is working with Visiopharm, an artificial intelligence (AI)-driven precision pathology software provider, to bring a wider range of AI products to doctors and patients. Visiopharm’s AI applications will be deployed and natively integrated into the Paige Platform to be accessed through FullFolio, Paige’s AI-powered clinical worklist, and viewed within FullFocus Paige’s whole-slide image viewer. This deep integration offers users greater diagnostic efficiency and quality insights when reviewing IHC-stained slides and creates a seamless user experience for Visiopharm’s image analysis applications, to help pathologists deliver faster, more accurate and more reproducible cancer diagnoses.

“With this partnership, Paige is furthering our aim to provide the richest portfolio of AI applications delivered through a single platform. In this way, we can increase the impact AI has in helping pathologists diagnose cancer and continue to make the adoption of digital pathology more productive.”

“Improving the pathologist experience to ultimately improve patient care is at the heart of our technology. The Paige and Visiopharm integration offers pathologists thorough image analysis and quantitative assistance on whole-slide images within one AI-native integrated platform,” said Dr. David Klimstra, Co-Founder and Chief Medical Officer of Paige. “With this partnership, Paige is furthering our aim to provide the richest portfolio of AI applications delivered through a single platform. In this way, we can increase the impact AI has in helping pathologists diagnose cancer and continue to make the adoption of digital pathology more productive.”

Latest Insights: Embrace AI to become a W.I.T.C.H. Leader

The Paige Platform is interoperable and designed to enable labs to deploy AI-based diagnostic products from AI vendors like Visiopharm, creating one seamless pathology workflow from a single interface. It also integrates with most major scanner vendors and allows bi-directional integration with LIS systems, facilitating a truly open and comprehensive experience.

Digital labs often employ digital technologies from different manufacturers for cancer diagnosis. With AI from Visiopharm and Paige together on a single platform, these labs can have streamlined access to digital images and combined insights together in one place.

Dr. Michael Grunkin, CEO of Visiopharm, stated, “Visiopharm, a global leader in AI-driven precision pathology, delivers standardized decision support for complex tissue biomarkers. Our fully automated (zero-click) applications use a cascade of deep learning networks for slide quality control, tissue detection, tumor identification, and biomarker quantification. Designed to work across various technologies and providers, we join Paige in our commitment to making this technology accessible worldwide on top pathology platforms.”

Latest Insights: Synthetic Data: A Game-Changer for Marketers or Just Another Fad?

[To share your insights with us, please write to sghosh@martechseries.com]

The post Paige and Visiopharm Work Together to Deliver Advanced AI Cancer Diagnostic Support Through the Paige Platform appeared first on AiThority.

Paige and Leica Biosystems Announce Expanded Partnership to Enhance Use of Image Management and Artificial Intelligence Technology

Business Wire — Mon, 13 Mar 2023 15:59:10 +0000

Leica Biosystems to adopt Paige’s image management and AI system for sale with Leica Biosystems Aperio digital pathology slide scanners

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, and Leica Biosystems, a cancer diagnostics company and global leader in workflow solutions, announced an expanded partnership to enhance the use of digital pathology workflows at hospitals and laboratories around the world. Building upon its existing partnership, Leica Biosystems has selected Paige as the preferred provider of software-as-a-service (SaaS) digital pathology image management and viewing software along with diverse embedded AI solutions for their line of Aperio GT 450 digital pathology slide scanners.

AiThority Interview : AiThority Interview with Shaun McGirr, Field CDO at Dataiku

“Our expanded partnership with Leica Biosystems reflects our unwavering commitment to deliver powerful AI applications to pathologists everywhere”

Leica Biosystems Aperio instrumentation is used in hospitals and laboratories around the world. Under the partnership, a co-branded version of Paige’s Platform will be introduced as the core interface between pathologists and Leica Biosystems hardware. Users of Aperio GT 450 scanners will have access to Paige’s full suite of digital pathology software, including the FullFocus® viewer; the AI-powered worklist FullFolio™; Paige Prostate Suite, which includes Paige Prostate Detect; Paige Breast Suite; Paige’s suite of biomarker algorithms; and all third-party AI software solutions deployed through Paige*.

“Our expanded partnership with Leica Biosystems reflects our unwavering commitment to deliver powerful AI applications to pathologists everywhere,” said Andy Moye, Ph.D., Chief Executive Officer at Paige. “With the widespread reach of Leica Biosystems scanners, we look forward to providing a seamless end-to-end solution that makes the transition to digital pathology easier for hospitals and laboratories around the world. The goal of our partnership is to help accelerate the ease of adoption of digital pathology and the efficiency with which pathologists can evaluate patient cases and to provide them with the insights needed to take decisive medical action.”

With a heritage of innovation spanning more than 150 years, Leica Biosystems has offered nine generations of continually improving digital slide scanning technology, realized in compact, user-friendly image capture devices that integrate with pathology workflows and laboratory information systems. Paige’s offerings include novel AI applications together with a powerful platform to easily view and manage whole slide images, putting the power of digital pathology into the hands of pathologists.

“As two global leaders in digital pathology, we have a shared goal of advancing the practice of pathology to improve patient care through innovative hardware and AI-driven software,” said Gustavo Perez, President of Leica Biosystems. “We believe that Paige’s differentiated platform and transformative portfolio of AI technologies will provide a streamlined user experience and help pathologists rapidly transition to digital workflows, enabling them to continue the fight against cancer.”

Latest Interview Insights : AiThority Interview with Jessica Stafford, SVP of Consumer Solutions at Cox Automotive

[To share your insights with us, please write to sghosh@martechseries.com]

The post Paige and Leica Biosystems Announce Expanded Partnership to Enhance Use of Image Management and Artificial Intelligence Technology appeared first on AiThority.

Paige and Mindpeak Launch an Integrated Solution for Enhanced Cancer Diagnosis

Business Wire — Sat, 11 Mar 2023 10:29:06 +0000

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, announced the availability of Mindpeak’s AI algorithms for IHC biomarker quantification in the Paige Platform. Mindpeak, a leader in image analysis AI software, brings state-of-the-art AI algorithms for analyzing IHC slides of lung and breast tissue into the Paige Platform. These two leading pathology AI providers have combined their technologies to help pathologists deliver faster, more accurate, and more reproducible quantitative cancer diagnoses, even in the most challenging and complex cases.

AiThority Interview : AiThority Interview with Shaun McGirr, Field CDO at Dataiku

“The Paige Platform is one of the most robust and easily integrated solutions available for both routine and AI-augmented digital workflows. The platform offers open compatibility with Mindpeak’s image analysis algorithms and AI solutions to support a complete and optimized workflow experience for pathologists”

This new integration allows a complete and seamless workflow on the Paige Platform through FullFocus, Paige’s FDA-cleared whole-slide image viewer*. The viewer provides case reviewing capabilities and access to AI, including Mindpeak’s quantitative immunohistochemistry (IHC) products that enable detection, classification, and quantification of immunolabeling results for lung (PD-L1) and breast (HER2, Ki-67, ER and PR) cancers.

“The Paige Platform is one of the most robust and easily integrated solutions available for both routine and AI-augmented digital workflows. The platform offers open compatibility with Mindpeak’s image analysis algorithms and AI solutions to support a complete and optimized workflow experience for pathologists,” said Felix Faber, CEO of Mindpeak. “Providing access to real-time results for breast and lung cancer IHC biomarkers enhances efficiency and accuracy of diagnosis and treatment planning to benefit pathologists, oncologists and patients, alike.”

“The Paige and Mindpeak integration highlights the Platform’s native AI deployment capabilities and provides real-time quantitative results for routine IHC biomarkers in lung and breast cancer,” said Dr. David Klimstra, Co-Founder and Chief Medical Officer of Paige. “The seamless integration into FullFocus allows pathologists to review all images from patients’ cases and immediately view results from Mindpeak’s AI-algorithms through a single interface at the slide-level or on regions of interest selected by the pathologist, improving day-to-day workflows without the need for multiple viewers and helping pathologists reproducibly quantify the expression of key predictive markers.”

Latest Interview Insights : AiThority Interview with Jessica Stafford, SVP of Consumer Solutions at Cox Automotive

[To share your insights with us, please write to sghosh@martechseries.com]

The post Paige and Mindpeak Launch an Integrated Solution for Enhanced Cancer Diagnosis appeared first on AiThority.